Zhejiang Chimin Pharm Co Ltd Total Assets

Latest as of June 2026: CN¥2.21 Billion CNY ≈ $323.44 Million USD

Zhejiang Chimin Pharm Co Ltd total assets. Based on the latest financial reports, Zhejiang Chimin Pharm Co Ltd (603222) holds total assets worth CN¥2.21 Billion CNY (≈ $323.44 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Zhejiang Chimin Pharm Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Total Assets of Zhejiang Chimin Pharm Co Ltd (2011–2025)

Total assets of Zhejiang Chimin Pharm Co Ltd from 2011 to 2025. This chart illustrates how Zhejiang Chimin Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Zhejiang Chimin Pharm Co Ltd for real-time trading data and today's change.

Zhejiang Chimin Pharm Co Ltd - Asset Composition Analysis

Zhejiang Chimin Pharm Co Ltd Total Assets Breakdown (December 2025)

Zhejiang Chimin Pharm Co Ltd total assets breakdown as of December 2025. Zhejiang Chimin Pharm Co Ltd's total assets of CN¥2.21 Billion consist of 25.3% current assets and 74.7% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 12.8%
Accounts Receivable CN¥115.82 Million 5.0%
Inventory CN¥112.69 Million 4.9%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥193.38 Million 8.4%
Goodwill CN¥14.75 Million 0.6%

Asset Composition Trend (2011–2025)

This chart illustrates how Zhejiang Chimin Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 603222 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Zhejiang Chimin Pharm Co Ltd's current assets represent 25.3% of total assets in 2025, a decrease from 59.7% in 2011.
  • Cash Position: Cash and equivalents constituted 12.8% of total assets in 2025, up from 4.7% in 2011.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, a decrease from 14.0% in 2011.
  • Asset Diversification: The largest asset category is intangible assets at 8.4% of total assets.

Zhejiang Chimin Pharm Co Ltd Competitors by Total Assets

Key competitors of Zhejiang Chimin Pharm Co Ltd based on total assets are shown below.

Company Country Total Assets
Ocumetics Technology Corp
V:OTC
Canada CA$1.15 Million
Nissan
TA:NISA
Israel ILA654.44 Million
Ansell Ltd
AU:ANN
Australia AU$3.39 Billion
Nanosonics Ltd
AU:NAN
Australia AU$279.25 Million
SDI Ltd
AU:SDI
Australia AU$135.84 Million
Austco Healthcare Ltd
AU:AHC
Australia AU$91.07 Million
Trajan Group Holdings Ltd
AU:TRJ
Australia AU$192.32 Million
Osteopore Ltd
AU:OSX
Australia AU$2.77 Million

Zhejiang Chimin Pharm Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.94 1.06 1.18
Quick Ratio 0.79 0.84 1.01
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-43.86 Million CN¥40.43 Million CN¥133.90 Million

Zhejiang Chimin Pharm Co Ltd - Advanced Valuation Insights

This section examines the relationship between Zhejiang Chimin Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.92
Latest Market Cap to Assets Ratio 0.24
Asset Growth Rate (YoY) -4.3%
Total Assets CN¥2.31 Billion
Market Capitalization $545.54 Million USD

Valuation Analysis

Below Book Valuation: The market values Zhejiang Chimin Pharm Co Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Zhejiang Chimin Pharm Co Ltd's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Zhejiang Chimin Pharm Co Ltd (2011–2025)

The table below shows the annual total assets of Zhejiang Chimin Pharm Co Ltd from 2011 to 2025.

Year Total Assets Change
2025-12-31 CN¥2.31 Billion
≈ $337.97 Million
-4.34%
2024-12-31 CN¥2.41 Billion
≈ $353.30 Million
-2.64%
2023-12-31 CN¥2.48 Billion
≈ $362.90 Million
-8.62%
2022-12-31 CN¥2.71 Billion
≈ $397.15 Million
+11.92%
2021-12-31 CN¥2.43 Billion
≈ $354.86 Million
+5.81%
2020-12-31 CN¥2.29 Billion
≈ $335.39 Million
+9.95%
2019-12-31 CN¥2.08 Billion
≈ $305.03 Million
-1.90%
2018-12-31 CN¥2.12 Billion
≈ $310.93 Million
+34.92%
2017-12-31 CN¥1.57 Billion
≈ $230.46 Million
+70.74%
2016-12-31 CN¥922.43 Million
≈ $134.98 Million
+9.29%
2015-12-31 CN¥844.01 Million
≈ $123.51 Million
+33.96%
2014-12-31 CN¥630.04 Million
≈ $92.19 Million
-11.68%
2013-12-31 CN¥713.38 Million
≈ $104.39 Million
+3.29%
2012-12-31 CN¥690.63 Million
≈ $101.06 Million
+5.39%
2011-12-31 CN¥655.30 Million
≈ $95.89 Million
--

About Zhejiang Chimin Pharm Co Ltd

SHG:603222 China Medical Instruments & Supplies
Market Cap
$545.54 Million
CN¥3.73 Billion CNY
Market Cap Rank
#11490 Global
#3212 in China
Share Price
CN¥7.10
Change (1 day)
+0.14%
52-Week Range
CN¥6.75 - CN¥11.27
All Time High
CN¥57.73
About

Chimin Health Management Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells in vitro diagnostic products and provides medical services in China and internationally. The company provides non-PVC double-pipe double-valve, single-pipe single-valve, and single-pipe double-valve soft bags; plastic bottles; and other packaging forms. It also offers injection puncture m… Read more